











EMCDDA–Europol Joint Report on a new 
psychoactive substance:  
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
acetamide (acetylfentanyl)
In accordance with Article 5 of Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of 
new psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In September 2015, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, commonly 
known as acetylfentanyl, through a joint assessment based 
upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information collected 
on acetylfentanyl satisfied criteria 1, 4, 6. The two agencies 
therefore concluded that sufficient information had been 
accumulated to merit the production of a Joint Report on 
acetylfentanyl as stipulated by Article 5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
22 September 2015 the EMCDDA and Europol launched a 
procedure for the collection of information on acetylfentanyl, 
in order to prepare the Joint Report. The information was 
collected mainly through the Reitox National Focal Points in 
the Member States, Turkey and Norway as well as the Europol 
National Units. In addition, the EMA collected information 
through the national competent authorities responsible for 
human and veterinary medicinal products in the Member 
States as well as in Norway, Iceland and Liechtenstein. The 
EMA also provided information as relevant to the centralised 
procedure for authorising medicinal products. The information 
collection process was largely concluded by 3 November 
2015; additional information and clarifications from some 
countries were received up to four weeks after this date.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
n  the level of production of acetylfentanyl in their country;
n  the level of distribution of acetylfentanyl in their country;
n  the level of trafficking of acetylfentanyl in their country, 
both for internal, transit or export purposes;
n  the number of seizures of acetylfentanyl in their country, 
the total amount of the seizures, country of origin, details 
on the physical forms (including photos);
n  the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of acetylfentanyl in 
their country; and,
n  any known aspect of violence and/or money laundering 
relating to the production and trafficking of acetylfentanyl.
Europol received responses from 10 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland, and Liechtenstein, provide 
information on whether:
n  the new psychoactive substance acetylfentanyl has 
obtained a marketing authorisation;
n  the new psychoactive substance acetylfentanyl is the 
subject of an application for a marketing authorisation; and,
n  a marketing authorisation that had been granted in respect 
of the new psychoactive substance acetylfentanyl has 
been suspended.
Twenty-four countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
(2)  In alphabetical order: Belgium, Bulgaria, Croatia, Cyprus, Finland, Germany, 
Hungary, Luxembourg, Portugal, and Slovakia.
(3)  Austria, Belgium, Denmark, Estonia, Germany, Greece, Hungary, Iceland, 
Ireland, Norway, Poland, Portugal, Slovakia, Sweden, and the United Kingdom 
provided a response in relation to human and veterinary medicinal products. 
Croatia and Spain provided a response in relation to human medicinal 
products. The Czech Republic, France, Italy, Latvia, the Netherlands, Romania, 
and Slovenia provided a response in relation to veterinary medicinal products.
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information on whether the new psychoactive substance 
acetylfentanyl is used to manufacture a medicinal product:
n  which has been granted a marketing authorisation;
n  for which an application has been made for a marketing 
authorisation; and,
n  for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-four countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
1.  a structured questionnaire to the Reitox National Focal 
Points. The EMCDDA received replies from all 28 Member 
States, as well as Turkey and Norway;
2.  reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
3.  routine monitoring of open source information;
4.  a specific information request to the World Health 
Organization on whether or not acetylfentanyl is under 
assessment by the United Nations system; and,
5.  a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’), and, online vendors 
selling acetylfentanyl.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part) (5). The information 
included in sections 3.8.3 (in part), 4.1, 4.2 and 4.3 was 
provided by the EMA. The conclusion of the Joint Report was 
prepared and agreed by the EMCDDA and Europol who are 
the two agencies responsible for the report.
(4)  Austria, Belgium, Denmark, Estonia, Germany, Greece, Hungary, Iceland, 
Ireland, Norway, Poland, Portugal, Sweden, and the United Kingdom provided 
a response in relation to human and veterinary medicinal products. Croatia 
and Spain provided a response in relation to human medicinal products. The 
Czech Republic, France, Italy, Latvia, the Netherlands, Romania, Slovakia, and 
Slovenia provided a response in relation to veterinary medicinal products.
(5)  The sections on chemistry, pharmacology and toxicology, dependence liability 
and abuse potential, and characteristics of users were produced in 
cooperation with Dr István Ujváry.
I 3.  Information required by Article 5.2 of 
the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
I 
3.1.  Chemical and physical description, including the 
names under which the new psychoactive 
substance is known (Article 5.2(a) of the Council 
Decision)
Chemical description and names
Acetylfentanyl belongs to the phenylpiperidine class of 
synthetic opioids. This class also includes fentanyl which is 
controlled under the United Nations Single Convention on 
Narcotic Drugs of 1961 (Schedule I). Structurally, 




The molecular structure, molecular formula, and molecular 
mass of acetylfentanyl are provided in in Figure 1.
Acetylfentanyl was first disclosed in patents by the Belgian 
company Research Laboratorium Dr. C. Janssen in the early 
1960’s (Janssen and Gardocki, 1964; Janssen, 1965; see also 
Janssen, 1962) (7). The analgesic activity of acetylfentanyl was 
first described in 1968 (Janssen and Van der Eycken, 1968).
Commonly used names: acetylfentanyl or acetyl fentanyl (8,9).
Systematic (IUPAC) name: N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl] acetamide.
Chemical Abstracts names: N-phenyl-N-[1-(2-phenylethyl)-4-
piperidinylacetamide; 1-phenethyl-4-(N-phenylacetamido)
piperidine; 1-phenethyl-4-(2-phenylacetamido)piperidine.
(6)  Which is why the substance is also called desmethyl fentanyl (i.e. 
desmethylated fentanyl).
(7)  The first patent for this group of compounds was filed by (the now called) 
Janssen Pharmaceutica (US Patent 3,141,823 (July 21, 1964), N.V., 4 pages). 
The corresponding and frequently cited patent application by Janssen (Fr M 
2340 of 27 April 1964; Chemical Abstract reference number: 62:14634) could 
not be located in the online French patent database.
(8)  Strictly speaking, neither name is correct: since fentanyl is a propionamide, so 
these two names actually refer to its acetylated derivative. A more appropriate 
designation would be ‘despropionyl acetyl fentanyl’.
(9)  A related homologous compound is acetyl-α-methylfentanyl. Its systematic 
name: N-phenyl-1-(1-phenylpropan-2-yl)acetamide; CAS RN 101860-00-8. It 
is included in Schedule I of the United Nations Single Convention on Narcotic 
Drugs of 1961.
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Other chemical names: 1-phenethyl-4-(N-phenylacetamido)
piperidine; N-(2-phenylethyl)-4-piperidylacetamide; N-[(1-(2-
phenylethyl)-4-piperidyl]-N-phenylacetamide.
Other names and code names: desmethyl fentanyl; 
desmethylfentanyl; fentanyl acetyl analog; fentanyl related 
compound G; fentanyl impurity C; NIH 10485; MCV 4848.
According to data submitted to the EMCDDA, ‘AF’ is used as a 
street name for acetylfentanyl. Acetylfentanyl has also been 
found in a substance/product known as ‘Valdiva’ (Sweden). 
Other street names for acetylfentanyl that were identified 
from open source information are listed below. It is important 
to note that many of these names are often used in a generic 
way to describe any fentanil that appear on the drug market: 
a-fent, ‘China White’ (misleading), ‘Apache’, ‘China girl’, ‘Dance 
fever’, ‘Friend’, ‘Goodfella’, ‘Jackpot’, ‘Murder 8’, ‘TNT’, and 
‘Tango and Cash’ (10,11).
(10)  These names were mentioned in news media: http://nationalpainreport.
com/health-officials-warn-of-fatal-fentanyl-overdoses-8820632.html 
(posted June 27 2013).
(11)  The last three names were mentioned in news media: http://www.mirror.
co.uk/news/uk-news/warning-over-legal-high-15-6619547 (12 October 
2015)




The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
results.
Physical description
Acetylfentanyl contains one basic nitrogen atom in the 
piperidine ring thus readily forming salts with organic or 
inorganic acids. The hydrochloride salt of acetylfentanyl is 
described in the literature as a white powder. The large 
majority of seized powders reported to the EMCDDA were 
white or off-white in colour. To a lesser extent, light-brown and 
light pink powders were also seized. There has been at least 
one seizure and one collected sample reported to the 
EMCDDA where acetylfentanyl was in the hydrochloride salt 
form.
FIGURE 1
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Acetylfentanyl is soluble in acidic media. According to 
information from a supplier of analytical reference materials 
‘acetyl fentanyl (hydrochloride)’ is soluble in phosphate buffer 
saline (pH = 7.2): ~10 mg per ml; in ethanol: ~20 mg/ml; in 
DMF: ~10 mg/ml and in DMSO: ~10 mg/ml (12,13).
Acetylfentanyl has been typically seized in powder form or in 
tablet form. It has also been detected in liquids, and, to a 
lesser extent, in capsules. A more detailed description of 
seizures and collected samples can be found in section 3.2.1 
and section 3.2.2.
I
 3.2.  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on 
the means and methods of manufacture of the 
new psychoactive substance (Article 5.2(b) of 
the Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1. Information provided to Europol
Europol received replies from 10 Member States (Belgium, 
Bulgaria, Croatia, Cyprus, Finland, Germany, Hungary, 
Luxembourg, Portugal, and Slovakia).
The majority of countries who provided information to Europol 
reported that they have no available information on 
acetylfentanyl.
Slovakia and Germany reported that according to their 
intelligence acetylfentanyl is used among drug users, however 
so far no seizures took place in these countries.
In addition, Germany informed that searches made on the 
internet have revealed, that acetylfentanyl is already known 
and occasionally discussed among Anglophone drug users 
and sometimes is offered via the Internet.
Two Member States (Belgium and Finland) reported seizures 
of acetylfentanyl (see below).
(12)  Available at: https://www .caymanchem.com/msdss/ISO00128m.pdf 
(accessed: 12 October, 2015)




The level of production
No information was received in relation to the production of 
acetylfentanyl.
The level of distribution
A total of seven seizures were reported to Europol: Belgium (4 
seizures), Finland (3).
Belgium
The Belgian Customs Service reported four seizures from 
June 2015. The packages were seized based on the customs 
legislation, because of under estimated value provided or an 
alert was provided to the destination country. The total 
amount of substance seized was 114 g.
Details of seizures:
First case: acetylfentanyl sourced in China and destined to a 
private person in Finland. The substance was declared as 
acrylic paint phenolic resin. The weight of substance in 
powder form together with a plastic package was 2.36 g. 
Belgian Customs reported this shipment to Finland, where the 
seizure was made.
Second case: acetylfentanyl sourced in China and destined to 
a private person in France. The substance was found in the 
plastic package labelled as ‘Hot melt powder’. The total weight 
of the substance and packaging material was 103.57 g. 
Custom services stopped the shipment because of under 
estimated value provided.
Third case: acetylfentanyl was sourced in China and destined 
to a private person in Germany. The substance was found in 
the small aluminium bag containing plastic package labelled 
as ‘Hot melt powder ‘. The total weight of the substance and 
packaging material was 11.30 g. Custom services stopped the 
shipment because of under estimated value provided.
Fourth case: acetylfentanyl was sourced in China and 
destined to a private person in Germany. The shipment was 
declared as a pentaerythritol. Inside a double aluminium bag, 
there was a plastic package containing three plastic sachets 
each containing powders. The content of the first sachet was 
identified as propylfentanyl (n-propylfentanyl or 
i-propylfentanyl, also known as butanoylfentanyl or iso-
butanoylfentanyl. Total weight including the plastic bag was 
2.42 g. The second sachet contained 2.41 g of acetylfentanyl, 
and the third bag contained 2.40 g of flubromazepam.
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Finland
Finland reported three minor postal seizures, which were 
seized in 2014. In two cases China was reported as the 
country of origin and in one case Belgium was reported as the 
country of origin. No further details concerning these seizures 
were provided to Europol.
The level of trafficking
Information related to trafficking routes is limited to the postal 
seizures mentioned above. In one of the cases, the package 
was sent from an address in Belgium, whereas in the 
remaining cases the packages originated from China.
Acetylfentanyl was destined for Finland in 4 cases, for 
Germany in 2 cases, and for France in 1 case.
3.2.2. Information provided to the EMCDDA
The EMCDDA received responses from all 28 Member States, 
as well as from Turkey and Norway. Of these, eight Member 
States (Belgium, Finland, France, Germany, Poland, Spain, 
Sweden, and the United Kingdom), and Norway reported 
detections of acetylfentanyl (14).
Seizures
In total, 78 seizures (15) have been reported to the EMCDDA by 
seven Member States and Norway: Belgium (4 seizures), 
Finland (5), France (2), Germany (1), Poland (2), Sweden (62), 
the United Kingdom (1), and Norway (1).
Seizures have been made at street-level (including 2 seizures 
made at the scene of death), as well as at national borders 
(including postal seizures originating from China).
These seizures included:
n  38 seizures of powders, in quantities ranging from 0.04 to 
252 g and colours varying between white/pink/beige/light 
brown;
(14)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities 
(police, customs, border guards, etc.). Collected samples are those that are 
actively collected by drug monitoring systems (such as test purchases) for 
monitoring and research purposes. Biological samples are those from 
human body fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.) 
(15)  Many ‘seizures’ relate to individual case-level data, however, some data 
provided to the EMCDDA are aggregated at the country level. Data is drawn 
from the Joint Report Questionnaires and data provided in the bi-annual 
data gathering (EU EWS Progress Reports and Final Reports) and from 
individual EMCDDA–Europol Reporting forms submitted to the EMCDDA on 
an ad hoc basis.
n  12 seizures of liquids (including nasal sprays and tinctures) 
in quantities ranging from 3 to 290 mL. Liquids were all 
clear/colourless with the exception of 1 red liquid;
n  24 seizures of tablets, in quantities ranging from 1 to 69 
units and colours varying between white/pink/red/beige/
light blue/light green;
n  1 seizure of tablets and powders made at the scene of a 
death associated with acetylfentanyl. This included olive 
coloured round tablets with the imprint ‘CDN’ and ‘80’ 
(reverse side), light blue round tablets with bisect bar and 
imprint ‘A/215’; and, an oval beige tablet with imprint 
‘Phantom’ and ‘100’ (reverse side). All samples contained 
acetylfentanyl, ANPP, and lactose. Of note is that the 
imprints of ‘CDN’/‘80’ and ‘A/125’ are also used on 
legitimate oxycodone-containing medicinal products. This 
finding may suggest that there are counterfeit medicinal 
products containing acetylfentanyl on the drug market;
n  1 seizure of powders and liquid made at the scene of a 
death associated with acetylfentanyl; and,
n  2 seizures of black-coloured capsules, one comprising of 
10 units and the other of 18 units.
Overall, the material seized amounted to 458.8 g of powder, 
454 tablets (and an additional 1.38 g of tablets in weight), 720 
mL of liquids, and 28 capsules.
It should be noted that these seizures are likely to represent an 
under-detection of acetylfentanyl. In part this is because in 
some cases acetylfentanyl is only tested for by forensic 
laboratories when specifically requested or when there are 
specific reasons to do so (16).
Acetylfentanyl was the only substance detected in 92% of the 
reported seizures. In the remaining 8% of seizures, other 
substances were detected. This included opioids and 
stimulants. Briefly:
n  Other opioids were found in 3 cases: one seizure of tablets 
contained acetylfentanyl and fentanyl; one seizure of a 
liquid (contained in a nasal spray) contained acetylfentanyl, 
U-47700, and butyrlfentanyl; a further seizure of liquid 
contained acetylfentanyl and U-47700.
n  4-ANPP(17): this substance can be both a synthetic 
precursor or a metabolite of acetylfentanyl. It was found in 
two seizures of powders, as well as in a variety of tablets of 
different colours found at the scene of a death.
n  Stimulants were present in 2 of the samples seized: in one 
case, α-PVP was the main constituent of the confiscated 
powder, and in another case traces of methamphetamine 
were found in a foil and spoon which were seized from the 
scene of death.
(16)  Information provided by the Member States, Turkey and Norway to the EMCDDA. 
(17)  4-anilino-N-phenylethylpiperidine.
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No quantitative information on purity was provided to the 
EMCDDA. In one seizure and one collected sample, 
acetylfentanyl in powder form was reported as being ‘almost 
pure’ hydrochloride form.
Lactose (which may be used as an excipient/diluent) was 
detected in some of the tablets that were seized.
Collected samples
Two Member States reported a total of 5 samples containing 
acetylfentanyl which were collected from users: France (2 
samples) and Spain (3). It is unknown where the users sourced 
the 2 samples reported by France. The 3 samples reported by 
Spain were purchased on the internet; in 2 of these cases it 
was reported to have been sold as butyr-fentanyl.
Biological samples
Four Member States (Germany, Poland, Sweden, and the 
United Kingdom) reported a total of 58 detections where 
acetylfentanyl was analytically confirmed in biological 
samples (18).
These related to:
n  40 serious adverse events (8 acute intoxications and 32 
deaths);
n  16 cases related either to patients undergoing drug 
treatment or cases related to persons suspected of having 
consumed drugs, committed minor offences, or crimes; 
and,
n  2 cases of persons suspected of driving under the 
influence of drugs.
I 
3.3.  Information on the involvement of organised 
crime in the manufacture or trafficking of the 
new psychoactive substance (Article 5.2(c) of 
the Council Decision)
No information was received in relation to the involvement of 
organised crime in the manufacture or trafficking of 
acetylfentanyl.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of 
acetylfentanyl.
(18)  A biological sample reported by Germany was excluded on the basis that 
there was no information reported in relation to the context of sampling.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of acetylfentanyl.
I 
3.4.  A first indication of the risks associated with the 
new psychoactive substance, including the 
health and social risks, and of the characteristics 
of users — Article 5.2(d) of the Council Decision 
3.4.1. Serious adverse events reported to the EMCDDA
Case-level data for 40 serious adverse events (19) associated 
with acetylfentanyl were reported to the EMCDDA by four 
Member States (Germany, Poland, Sweden, and the United 
Kingdom). These cases comprised 8 acute intoxications and 
32 deaths. An overview of these data is presented below.
Acute intoxications
Case-level data for 8 acute intoxications associated with 
acetylfentanyl were reported by Sweden. All the cases 
presented to hospital emergency departments. Acetylfentanyl 
was analytically confirmed in all the cases. All the cases 
occurred in 2015. Six of the eight cases were classified as 
non-fatal intoxications; in the remaining two cases the 
outcome of the intoxication was unknown.
Demographics
Seven of the acute intoxications were male; one was female. 
The mean age of the male case was 26 years (median 27); the 
female case was aged 35.
Substances analytically identified
Alongside acetylfentanyl, benzodiazepines and/or their 
metabolites were detected in all 8 cases. Other substances 
were detected in 6 of the cases. These included: opioids and/
or their metabolites; ethanol and metabolites; and stimulants. 
(19)  Serious adverse event means any adverse event, whether analytically 
confirmed or not, that is associated with the consumption of a new 
psychoactive substance in a human that: results in death; is life-
threatening; requires intensive treatment in an emergency room and/or 
requires hospitalisation; results in persistent or significant disability or 
incapacity; results in substance dependency or substance abuse; consists of 
a congenital anomaly or birth defect; or is an important medical event that 
may not be immediately life-threatening or result in death or hospitalisation 
but may jeopardise the patient or may require intervention to prevent one of 
the other outcomes listed above. Examples of such events are: convulsions 
that do not result in hospitalisation.
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Some of the substances that were detected included 
authorised medicinal products; it is unknown if these had 
been prescribed to the patients.
Clinical features
Data on the clinical features (20) related to the 8 acute 
intoxications were generally consistent with opioid toxicity (in 
particular the opioid overdose triad). Other symptoms were 
reported, albeit less frequently.
Clinical features were reported for all 8 cases. They included: 
unconsciousness (5 cases), miosis (4), respiratory depression 
(3), somnolence (2), rhabdomyolysis (2), hyperthermia (2), 
kidney failure (2). Features reported only once included: 
cardiac arrest, cyanosis, hypotension, aspiration pneumonia, 
urine retention, agitation, convulsions, slurred speech, 
tachycardia, and mydriasis.
Seriousness and outcome
In 7 of the 8 cases, the seriousness of the intoxication was 
classified as life-threatening; the remaining case was 
classified as not life-threatening but requiring treatment in 
hospital.
In respect to the outcome of the intoxication:
n  In 5 cases the patients were reported to have recovered;
n  In 1 case the patient was reported as recovering; and,
n  In 2 cases the outcome was unknown.
Route of administration
The route of administration was only known for one case. Here, 
the patient was reported to have snorted acetylfentanyl as a 
powder.
Name of the substance/product used
The name of the substance taken by the patient was reported 
for 5 cases:
n  in 3 cases the patients were reported to have taken 
‘acetylfentanyl’;
n  in 1 case, the patient was reported to have taken ‘Xanor-
stavar’;
n  in 1 case the patient was reported to have taken a 
powdered substance called ‘Valdiva’ which was sourced 
from the Internet apparently under this name (see below).
(20) Includes an abnormal laboratory finding. 
Source of the substance
Information on where the patients had sourced the substance 
was available in 3 cases: in all of them acetylfentanyl was 
sourced from the internet. In 1 of these cases it was reported 
that the substance was sourced as acetylfentanyl while in 
another case the substance was sourced as ‘Valdiva’.
Physical form
Information on the physical form of acetylfentanyl used by the 
patients was available in 3 cases: 2 of them used a powder 
(one of which was reported to be ‘Valdiva’) and the remaining 
case was reported to have used tablets (‘Xanor-stavar’).
Amount or dose administered
No information was reported on the amount of acetylfentanyl 
used by the patients.
Deaths
Case-level data for 32 deaths associated with acetylfentanyl 
were reported by four Member States: Germany (2 cases), 
Poland (1) (21), Sweden (27), and the United Kingdom (2). 
Acetylfentanyl was analytically confirmed in all 32 cases.
Demographics
Of the 32 deaths, 26 were male (81%) and 6 were female 
(19%). The decedents ages ranged from 21 to 56 years old. 
The mean age of the male decedents was 32 years (median 
31); the mean age of the female decedents was 37 years 
(median 34).
Number of deaths by year
One death occurred in 2013; 2 deaths occurred in 2014; 29 
(90.6%) deaths occurred in 2015 (January–September). 
Overall, 13 (40%) deaths occurred in August 2015.
Cause of death
The cause of death was reported in 20 cases. For the 
remaining 12 cases the cause of death was unknown at the 
time of reporting to the EMCDDA.
In 19 of the 20 cases where the cause of death was reported, 
acetylfentanyl was either reported as the cause of death (11 
cases) or as a contributing factor (8); in the remaining case an 
(21)  The analytical confirmation of acetylfentanyl in the death reported by Poland 
is based on a preliminary report.
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alternative cause of death was reported (‘intoxication with 
narcotics’).
In 2 deaths acetylfentanyl was the only substance detected; in 
both these cases acetylfentanyl was reported as the cause of 
death. Other substances were detected in the remaining 30 
deaths. These included: benzodiazepines and their metabolites, 
opioids (including fentanyl and derivatives, and buprenorphine), 
antidepressants and antipsychotics, THC, synthetic 
cannabinoids, cocaine, amphetamine, methamphetamine, 
MDMA, methylphenidate, methoxetamine, α-PVT and MDPBP.
Route of administration
The route of administration was known for 3 of the 32 deaths: 
in two cases circumstantial evidence suggests that the 
acetylfentanyl was injected; in the third case the substance 
was presumed to be snorted.
Source
Information on where the decedents had sourced the 
substance was available in 3 cases: in all of them 
acetylfentanyl was sourced from the internet.
Amount or dose administered
No information was reported on the amount of substance 
administered by the decedents.
3.4.2.  Serious adverse events identified in open source 
information
Since 2012, more than 50 deaths associated with 
acetylfentanyl have been reported in Russia (12 deaths) 
(Melen’tev et al., 2015) and in the United States of America 
(>40 deaths) (Drug Enforcement Administration, 2015a; Drug 
Enforcement Administration, 2015b; Centers for Disease 
Control and Prevention, 2013a; Centers for Disease Control and 
Prevention, 2013b; Lozier et al., 2015; Isenschmid et al., 2014; 
Isenschmid et al., 2015; McIntyre et al., 2015; Cunningham et 
al., 2015; Poklis et al., 2015; Zhang et al., 2015).
Investigations into these deaths suggest that those who use 
acetylfentanyl include individuals who use illicit opioids, such 
as heroin and/or prescription opioids.
3.4.3. Pharmacology
Overview
Published data on the pharmacology of acetylfentanyl are 
limited to nonclinical studies. These data suggests that 
acetylfentanyl is a potent and selective μ-opioid receptor 
agonist with some broad similarities to fentanyl.
Further research is required in order to have a more detailed 
understanding of the mode and mechanism of action of 
acetylfentanyl, including abuse liability and dependence 
potential, and how this relates to humans. This should also 
include study of the pharmacological effects of acetylfentanyl 
on other neurotransmitter systems as well as the 
pharmacological effects of the metabolites of acetylfentanyl.
Pharmacodynamics
In vivo and ex vivo data
Acetylfentanyl has been shown to bind to μ-opioid receptors 
in rat cerebrum membrane preparations (Woods et al., 1988). 
In a binding assay using a rat brain opioid receptor preparation 
and the non-selective opioid receptor agonist [3H]etorphine as 
radioligand, the EC
50
 values (22) for morphine and 
acetylfentanyl were 23.6 and 676 nM, respectively, indicating 
that acetylfentanyl is about 25-times less potent than 
morphine as an opioid receptor ligand in this assay (Woods et 
al., 1988). In comparison, the EC
50
 value for fentanyl is 36.2 
nM, indicating that fentanyl is somewhat less potent than 
morphine in this assay (Woods et al., 1998).
Pharmacological investigation of the degree of inhibition of 
electrically induced contractions of a mouse vas deferens 
preparation (23) showed that acetylfentanyl produces a more 
potent analgesic response in mice than that of morphine, but 
slightly less potent than fentanyl. In one study, acetylfentanyl 
was shown to display opioid receptor agonist activity with 
EC
50
 values of 4420 nM compared to 395 nM for morphine 
(Woods et al., 1988). The reported EC
50
 value for fentanyl was 
37.1 nM (Woods et al., 1998).
The receptor selectivity of acetylfentanyl was also assessed 
by the MVD-assay in the presence of selective μ-opioid 
receptors (MOR) or δ-opioid receptor (DOR) antagonists 
(Woods et al., 1988). Pre-treatment of the mouse vas deferens 
preparation with the irreversible but non-competitive MOR-
selective antagonist funaltrexamine the binding acetylfentanyl 
(22)  EC
50
 refers to the half maximal effective molar concentration of a drug that 
produces 50% of its maximal possible effect.
(23)  Mouse vas deferens contains multiple opioid receptors and has been a 
traditional assay for opioid actions outside the central nervous system.
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was unaffected ([3H]etorphine-binding related EC
50
 value = 
4800 nM) but the effect of acetylfentanyl on the inhibition of 
the electrically induced contractions of mouse vas deferens 
diminished (29.3%); furthermore, the selective DOR 
antagonist ICI-174864 failed to affect acetylfentanyl-inhibited 
etorphine binding (EC
50
 = 5170 nM) in the mouse vas deferens 
preparation. These experiments indicate that acetylfentanyl is 
a selective MOR agonist.
Animal studies
Acetylfentanyl is about 15 times more effective as an 
antinoceptive (24) agent than morphine, as shown by the 
acetic acid writhing test (Higashikawa and Suzuki, 2008). 
Potency of acetylfentanyl was about 3-fold less than that of 
fentanyl in this assay. The ED
50
 dose (the dose at which 50% of 
test animals had met the criterion for analgesic response) for 
acetylfentanyl, fentanyl and morphine were 0.021, 0.0061, 
and 0.33 mg/kg, respectively.
Pharmacokinetics
Due to its lipophilicity, acetylfentanyl, like fentanyl, is expected 
to readily cross the blood–brain barrier and also diffuse into 
fat and other tissues.
Nonclinical data on the metabolism of acetylfentanyl is not 
available. Published information from acetylfentanyl post-
mortem cases (Finkelstein et al., 2015; Zhang et al., 2015; 
Cunningham et al., 2015; Hitsasune et al., 2015; K. Hitsasune, 
personal communication; Patton et al., 2014) as well as 
comparison to nonclinical data available for fentanyl 
(Goromaru et al., 1984; Guitton et al., 1997; DePriest et al., 
2015) can provide some information as to the 
pharmacokinetics and metabolism of the substance.
Recently, the chemical structures of the main Phase I 
metabolites present in the urine of acetylfentanyl consumers 
have been determined (Melent’ev et al., 2015) and three key 
metabolic steps were proposed which involved hydroxylation 
(to give phenols), dealkylation (to give acetyl norfentanyl) and 
de-acetylation (to give 4-ANPP).
Limited information is available on the pharmacological 
effects of the metabolites acetylfentanyl. An early study by 
Schneider and Brune (1986) found that 4-ANPP and 
4-anilinopiperidine, both of which are formed during the 
metabolism of acetylfentanyl, were less potent than fentanyl 
by four to five orders of magnitude. Compared to morphine, 
these two anilines were less active by three to four orders of 
magnitude. The only metabolite showing significant activity in 
(24)  Antinoceptive agent: refers to the ability that a substance has to inhibit 
nociception, i.e. to inhibit the sensation of pain.
this assay was a phenolic derivative hydroxylated at the 
4-position of the phenylethyl moiety of fentanyl (25) the activity 
of which was found to lie between morphine and pethidine.
Accordingly, the corresponding phenolic metabolite of 
acetylfentanyl may have some level of opioid activity and thus 
contribute to the biological, including toxicological, properties 
of the parent substance.
Abuse liability and dependence potential
The dependence liability of acetylfentanyl in morphine-
dependent rhesus monkeys was assessed in the ‘single-dose 
suppression’ (SDS) model of morphine withdrawal (Aceto et 
al., 1988). A dose of 0.5 mg/kg of subcutaneous injected 
acetylfentanyl briefly (for about 90 min) substituted 
completely for morphine; the effect of morphine injection in 
alleviating withdrawal symptoms lasted for a longer period. At 
peak effect, acetylfentanyl could thus be considered to be 
six-times as potent as morphine in this test.
No data are available from clinical studies on the abuse 
liability and dependence potential of acetylfentanyl in 
humans.
Limited information from self-reported user experiences on 
user websites appear to suggest an abuse potential and the 
development of tolerance.
Overall, the available data suggests that acetylfentanyl may 
have an abuse liability and dependence potential in humans.
3.4.4. Toxicology
Animal data
There is limited information on the toxicity of acetylfentanyl. In 
mice, the acute LD
50
 value of acetylfentanyl upon 
intraperitoneal injection is 9.3 mg/kg (Higashikawa and 
Suzuki, 2008). The LD
50
 values reported in the same study for 
morphine and fentanyl are 470 and 62 mg/kg, respectively, 
which suggests that acetylfentanyl is several times more toxic 
than fentanyl, at least in rodents (26).





 values) for acetylfentanyl can be considered relatively 
small (440-fold) when compared to morphine (1420) and 
(25)  Of the potential mono- and dihydroxylated metabolites only this substance 
was tested (that is N-{1-[2-(4-hydroxyphenyl)ethyl]piperidin-4-yl}-N-
phenylpropionamide.
(26)  For comparison, the respective intravenous LD
50
 values in mice for morphine 
and fentanyl were found to be 270 and 11.2 mg/kg (Gardocki and Yelnosky, 
1964).
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fentanyl (10100). This indicates that the difference between 
the toxic dose and the effective antinociceptive dose for 
acetylfentanyl in mice is narrower than the respective 
differences for morphine and fentanyl (27).
Autopsy of the animals that died in the oral toxicity 
experiments revealed that there was significant bleeding in 
the small intestine, which was presumed to be one of the 
causes of death.
There are no reports on the chronic toxicity of acetylfentanyl.
Human data
Data from serious adverse events associated with 
acetylfentanyl are discussed above (Section 3.4.1). Based on 
limited data, it appears that the toxidrome of acetylfentanyl 
may be broadly similar to other fentanils and narcotic-
analgesic opioids. This includes the opioid overdose triad of 
miosis, unconsciousness, and respiratory depression.
3.4.5. Characteristics of users
Data on the characteristics of users of acetylfentanyl is 
limited.
It is important to note that when interpreting the data on 
self-reported user experiences that is provided in this report, it 
is not possible to confirm the specific substance(s) used; 
similarly it is also not possible to confirm the strength, purity, 
dose/amount, etc., used. In addition, the information provided 
on user websites and from specific user groups may not 
necessarily be representative of other users of acetylfentanyl 
and should be regarded as illustrative only.
Route of administration, dose, drug regimens and 
settings of use
Routes of administration include snorting, smoking/inhalation, 
oral (ingestion as powder, in capsules, tablets or as tinctures), 
nasal (using sprays), and injection (intravenous). Smokeable 
herbal preparations have also been noted in open source 
information but this route has not been reported by any of the 
Member States.
The salt form of acetylfentanyl is water soluble and therefore 
could be administered by injection. The free base is poorly 
(27)  These estimates are only applicable to oral administration in the 
experimental mice. The TI value could be different upon injection use in 
humans with the intention to achieve psychoactive effects.
soluble in water and can be smoked, vaporised or nasally 
administered (28).
The available data suggests that polydrug use might be 
common in those using acetylfentanyl.
Dose, re-dosing
As with all psychoactive substances, the dose required to 
attain the desired effects depends on the route of 
administration. The available data, however, does not allow the 
identification of common/typical doses of acetylfentanyl 
regardless of route.
France reported a case where an individual self-reported 
having injected 10mg of acetylfentanyl, with a total of 30mg 
administered over a 12 hour period. The individual reported 
feeling ‘on the verge of dying’.
There are no clinical studies on the doses required to produce 
subjective effects of acetylfentanyl in humans. Limited data 
from self-reported user experiences posted on user websites 
mention that doses of acetylfentanyl from 3 to 10mg are 
needed to notice ‘opioid-like psychoactivity’, administered 
either by injection or nasal insufflation.
Subjective, psychological, and behavioural effects
Discussions on user websites suggest that the subjective 
effects of acetylfentanyl are similar to that of other opioids and 
characterised by relaxation and euphoria (Gorodetzky and 
Martin, 1965). Nausea and vomiting have been mentioned as 
unintended effects. Information provided in some user 
experiences are consistent with symptoms of dependence (29).
There are no clinical studies assessing the psychological and/
or behavioural effects of acetylfentanyl in humans. Limited 
data from serious adverse events and user websites suggest 
that the effects of acetylfentanyl resemble those of other 
narcotic-analgesic opioids.
Effect on ability to operate machinery and drive
Based on limited data from nonclinical studies, serious 
adverse events, and self-reported user experiences, it may be 
assumed that the acute behavioural effects of acetylfentanyl 
on operating machinery and driving are similar to those 
caused by other opioid-type narcotic-analgesics.









A structured search by the EMCDDA of online vendors (30) of 
acetylfentanyl on the surface web (31) was conducted in 
November 2015. The search identified 8 vendors that 
appeared to be based in, and/or claim to have presence in 
China (n=5 sites) and India (n=1 sites). For the remaining 2 
vendors there was no apparent location mentioned. Four of 
the sites only provided quantities and prices for acetylfentanyl 
on application. The remaining 4 sites listed quantities and 
prices. Briefly:
n  on these sites acetylfentanyl was typically sold as a 
‘research chemical’;
n  the minimum quantity offered was 10 mg (n=1 sites) with a 
price of EUR 183.31;
n  the maximum quantity offered was 1 kg (n=1 sites) with a 
price of EUR 7,000;
n  2 of the 4 sites listed prices for 1g, for which the mean 
price was EUR 23.50; and,
n  1 of the 4 sites listed prices for other quantities:
– The price for 10g was EUR 159.8 (EUR 15.98/g);
– The price for 100g was EUR 846 (EUR 8.46/g);
– The price for 1kg was EUR 6580 (EUR 6.58/g);
Prices were listed in United States Dollars on all 4 sites (32).
A similar search had been conducted in July 2015 and 
identified 19 vendors that appeared to be based in, and/or 
claim to have presence in China (n=11 sites), the United States 
of America (n=3) and India (n=1). For the remaining 4 vendors 
there was no apparent location mentioned.
There was change in the legal status of acetylfentanyl in China 
(section 3.7) between the dates of the two searches, but it is 
not clear what effect this has had on the online availability of 
acetylfentanyl on the surface web.
Prevalence of use
There appear to be no data from general population surveys or 
targeted surveys on the prevalence of acetylfentanyl use.
(30)  This includes vendors that appear to be consumer-orientated as well as 
vendors, for example on B2B sites, which appear to be manufacturers and/or 
wholesalers. It excludes those selling acetylfentanyl through online classified 
advertisements, social media, and user websites.
(31)  The search of online vendors of acetylfentanyl was performed on google.
co.uk on 17/11/2015 using the search strings: ‘buy acetylfentanyl’. The first 
100 results were recorded and the sites reviewed. Each identified vendor site 
was then scored for information on warehouse location, quantities and 
prices, and substance marketing.
(32)  Prices listed in USD were converted to EUR according to Google exchange 
rate from the 17.11.2015 (USD 1 = EUR 0,94). 
Information on the use of acetylfentanyl in Europe is mostly 
limited to discussions on user websites (33,34). From these 
discussions, it appears that acetylfentanyl is used by 
psychonauts and users with experience of other opioids.
Information from open source information suggests that user 
groups in the United States of America include individuals 
who use illicit opioids, such as heroin and/or prescription 
opioids.
I 3.5.  Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system (Article 5.2(e) of the Council Decision)
The World Health Organization (WHO) is the specialised 
United Nations agency designated for the evaluation of the 
medical, scientific and public health aspects of psychoactive 
substances under the United Nations Single Convention on 
Narcotic Drugs of 1961 and the United Nations Convention on 
Psychotropic Substances of 1971.
On 24 November 2015, WHO informed the EMCDDA that 
acetylfentanyl is currently under assessment by the United 
Nations system. Specifically, WHO reported that a critical 
review of acetylfentanyl has been published and the 
substance was assessed at the Thirty-Seventh meeting of the 
WHO Expert Committee on Drug Dependence (ECDD) that 
was held 16–20 November 2015. A recommendation from the 
assessment had not been published at the time of drafting 
this Joint Report.
I 3.6.  The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
The first official EMCDDA–Europol notification of 
acetylfentanyl dates from September 2014 from the Polish 
National Focal Point. The Reporting Form details a seizure of 
20.2 g of white powder, also containing 4-anilino-N-
phenethylpiperidine (4-ANPP (a precursor used in fentanyl 
production) that was seized in March 2014 by the Polish 
Customs authorities in Warsaw, Poland. The identification and 




(34)  https://www.google.pt/search?client=safari&rls=en&q=site:drugs- 
forum.com+acetylfentanyl+OR+acetyl+fentanyl&ie=UTF-8&oe=UTF8&gfe_
rd=cr&ei=_Tl0VaWQDYys8wfc2IDYAQ
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chromatography-mass spectrometry (GC-MS)and Infrared (IR) 
spectroscopy.
Acetylfentanyl was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System and a profile of the 
substance was created on the European Database on New 
Drugs (EDND). Since then, analytical details and other 
information, including public health alerts, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey, and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
It is important to note that data provided by Germany as part 
of the data collection process for the Joint Report suggests 
that acetylfentanyl has been present on the European drugs 
market since at least 2013, as evidenced by a seizure of the 
substance made at a scene of a death.
I 3.7.  Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State (Article 5.2(g) of the Council Decision)
Nine Member States (Austria, Cyprus, Estonia, Finland, 
Ireland, Latvia, Lithuania, Sweden, and the United Kingdom) 
reported that acetylfentanyl is controlled under drug control 
legislation.
n  In Austria, acetylfentanyl has been listed in Annex 1 of the 
Narcotic Substances Regulation.
n  In Cyprus, acetylfentanyl has been controlled since 2013 
via a Regulatory Administrative Act, ΚΔΠ 162/13, within 
the updates of the law L29/77. It is controlled within the 
context of a generic clause which addresses all fentanyl 
chemical groups.
n  In Estonia, acetylfentanyl has been added to drug control 
legislation since 8 June 2015.
n  In Finland, acetylfentanyl is controlled as a narcotic 
substance and has been listed in Annex 4 (Liite 4) of drug 
control legislation since 28 September 2015.
n  In Ireland, acetylfentanyl is controlled under schedule I of 
the Misuse of Drugs Regulation 1988 (S.I. 328 of 1988).
n  In Latvia, acetylfentanyl is included in the first list of the 
Cabinet Regulation N 847 ‘Regulations regarding Narcotic 
Substances, Psychotropic Substances and Precursors to 
be Controlled in Latvia’ and the law ‘On the Procedures 
for the Coming into force and Application of the Criminal 
Law’.
n  In Lithuania, acetylfentanyl has been placed under control, 
according to the Republic of Lithuania Minister of Health 
Order No V-1062 (21/09/2015) ‘On the amendment of the 
Ministry of Health of the Republic of Lithuania Order No. 5 
of 6 January 2000 ‘On approval of the narcotic and 
psychotropic substances lists’.
n  In Sweden, acetylfentanyl has been regulated since the 18 
August 2015.
n  In the United Kingdom, acetylfentanyl is controlled as a 
Class A substance under the Misuse of Drugs Act 1971 
(Modification) Order 1986, No. 2230.
One Member State (Poland) reported that acetylfentanyl is 
controlled under specific new psychoactive substances 
control legislation. Specifically, acetylfentanyl is controlled 
according to the general definition of the ‘substitute drug’ 
which has been included to the Act of 8 October 2010 
amending the Act on counteracting drug addiction and the Act 
on State Sanitary Inspection (Journal of Laws ‘Dz.U.’ No. 213, 
item 1396). Article 44b of the above mentioned Act bans 
manufacturing or introducing substitute drugs to trade.
In Norway, the import of and trade in acetylfentanyl is 
controlled by the Medicines Act. Norway also reported that 
acetylfentanyl will be assessed for listing as a controlled 
substance (narcotic substance).
Eighteen Member States (Belgium, Bulgaria, Croatia, Czech 
Republic, Denmark, France, Germany, Greece, Hungary, Italy, 
Luxembourg, Malta, Netherlands, Portugal, Romania, Slovakia, 
Slovenia, and Spain) and Turkey reported that acetylfentanyl is 
not subject to control measures at the national level.
Finally, it is noteworthy that the People’s Republic of China 
placed acetylfentanyl under national drug control legislation 
on the 1 October 2015.
I 3.8.  Further information (Article 5.2(h) of the Council Decision)
3.8.1.  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey, or 
Norway, about the chemical precursors or manufacturing 
methods used to make the acetylfentanyl which has been 
detected within Europe.
A limited number of publications describe the synthesis of 
acetylfentanyl (Janssen, 1965; Brine et al., 1989; Carroll et al., 
1990; Fritschi and Klein, 1995; Valdez et al., 2014). In addition, 
there are several documented methods for the production of 
fentanyl in the scientific literature, which, in principle, could be 
applied to the synthesis of acetylfentanyl (provided that acetic 
acid anhydride or acetyl chloride is used in the acylation step). 
The direct conversion of fentanyl into acetylfentanyl would be 
circuitous thus impractical (Soine, 1986; Carroll and Brine, 
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1989; Hsu and Banks, 1992; Yadav et al., 2010; Vardanyan and 
Hruby, 2015).
Most of the synthetic procedures are straightforward and use 
common laboratory equipment, and only a basic knowledge of 
synthetic chemistry is required. Nonetheless, the final steps of 
purification and isolation of the products may pose significant 
risk to the operator due to the high potency of the final 
products.
Condensation of commercially available 1-benzyl-4-
piperidinone (35) with aniline in the presence of an acid 
catalyst provides the corresponding imine (Schiff base), which 
is then reduced by lithium aluminum hydride to the 1-benzyl-
N-phenylpiperidine-4-amine. Acylation of this anilinopiperidine 
with acetic acid anhydride affords N-(1-benzylpiperidin-4-yl)-
N-phenylacetamide (36).
Removal of the benzyl protective group by catalytic 
hydrogenation using palladium-on-carbon catalyst is followed 
by alkylation of the piperidine with (2-haloethyl)benzene in the 
presence of an acid scavenger such as sodium carbonate to 
give acetylfentanyl.
More straightforward methods have been developed since 
then, including a ‘one-pot’ synthesis which is available 
online (37). This route (frequently called the ‘Siegfried method’) 
has not specifically been described in the literature. The 
detection of 4-ANPP as contaminant in seized samples of 
acetylfentanyl and the availability of this 4-ANPP on the 
chemicals market suggest its use as precursor in the 
manufacture of the acetylfentanyl (or, possible, other 
uncontrolled and yet undetected acyl analogues of fentanyl).
Lurie and co-workers (Lurie et al., 2012) suggest that the 
detection of N-benzylpiperidine-type contaminants, such as 
‘N-benzyl-acetylfentanyl’, in seized samples indicates that the 
substance was produced by the original Janssen method, 
while the presence of 4-ANPP as impurity in the samples 
suggests the use of the ‘Siegfried method’.
Acetic anhydride, one of the precursors needed for the 
synthetic pathways described above, is included in the United 
Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988.
(35)  The three-step synthesis of N-benzylpiperidinone and other 
N-aralkylpiperidinones from benzylamine or the appropriate aralkylamine 
and ethyl (or methyl) acrylate is well documented.
(36)  A recent small seizure in Finland of N-(1-benzylpiperidin-4-yl)-N-(4-
fluorophenyl)butanamide (or isomers) indicates the potential use of this 
route for the production of unregulated fentanyl analogues.Alternatively, 
such precursors can be offered on their own right as fentanyl analogues 
although limited information indicates that such N-benzyl piperidines are 
poorly active as analgesics (see, for example, Casy et al., 1969).
(37)  See, for example, http://opioids.com/fentanyl/synthesis.html 
3.8.2.  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of acetylfentanyl. Given 
the limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3.  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive substance, 
including the health and social risks
No information was provided by any Member State that 
indicated that acetylfentanyl had any other use apart from in 
analytical reference materials and scientific research.
From the available information, it does not appear that 
acetylfentanyl is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a European Union 
database on the synthetic route of all medicinal products.
Six countries (Austria, Denmark, Hungary, Poland, Spain, and 
the United Kingdom) reported that acetylfentanyl is not used 
to manufacture a medicinal product for human use. Eleven 
countries (Belgium, Croatia, Estonia, Germany, Greece, 
Iceland, Ireland, Norway, Portugal, Slovakia, and Sweden) 
reported that it was unknown if acetylfentanyl is used to 
manufacture a medicinal product for human use.
Nine countries (Austria, Czech Republic, Denmark, France, 
Latvia, Poland, Portugal, Romania, and the United Kingdom) 
provided information that acetylfentanyl is not used to 
manufacture a medicinal product for veterinary use. Thirteen 
countries (Belgium, Estonia, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, the Netherlands, Norway, Slovakia, 
Slovenia, and Sweden) reported that it was unknown if 
acetylfentanyl is used to manufacture a medicinal product for 
veterinary use.
In addition, the EMA reported that it is not known if 
acetylfentanyl is used in the manufacture of medicinal 
products for human or veterinary use and which are centrally 
authorised within the European Union.
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I 4.  Information from the EMA (Article 5.3 of the Council Decision)
I 4.1. Marketing authorization
Seventeen countries (Austria, Belgium, Croatia, Denmark, 
Estonia, Germany, Greece, Hungary, Iceland, Ireland, Norway, 
Poland, Portugal, Slovakia, Spain, Sweden, and the United 
Kingdom) reported that acetylfentanyl has not been granted a 
marketing authorization as a medicinal product for human use.
Twenty two countries (Austria, Belgium, Czech Republic, 
Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, 
Portugal, Romania, Slovakia, Slovenia, Sweden, and the United 
Kingdom) reported that acetylfentanyl has not been granted a 
marketing authorization as a medicinal product for veterinary 
use.
The EMA also reported that acetylfentanyl has not been 
granted a marketing authorization as a medicinal product for 
neither human nor veterinary use through the centralized 
procedure.
I 4.2. Application for a marketing authorization
Seventeen countries (Austria, Belgium, Croatia, Denmark, 
Estonia, Germany, Greece, Hungary, Iceland, Ireland, Norway, 
Poland, Portugal, Slovakia, Spain, Sweden, and the United 
Kingdom) reported that acetylfentanyl is not the subject of an 
application for a marketing authorization as a medicinal 
product for human use.
Twenty two countries (Austria, Belgium, Czech Republic, 
Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, 
Portugal, Romania, Slovakia, Slovenia, Sweden, and the United 
Kingdom) reported that acetylfentanyl is not the subject of an 
application for a marketing authorization as a medicinal 
product for veterinary use.
The EMA also reported that acetylfentanyl is not the subject of 
an application for a marketing authorization for neither human 
nor veterinary use through the centralized procedure.
I 4.3. Suspended marketing authorization
Seventeen countries (Austria, Belgium, Croatia, Denmark, 
Estonia, Germany, Greece, Hungary, Iceland, Ireland, Norway, 
Poland, Portugal, Slovakia, Spain, Sweden, and the United 
Kingdom) reported that that there had been no cases of 
suspended marketing authorization granted in respect to 
acetylfentanyl as a human medicine.
Twenty two countries (Austria, Belgium, Czech Republic, 
Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, 
Portugal, Romania, Slovakia, Slovenia, Sweden, and the United 
Kingdom) reported that that there had been no cases of 
suspended marketing authorization granted in respect to 
acetylfentanyl as a veterinary medicine.
The EMA also reported that acetylfentanyl is not the subject of 
a suspended marketing authorization for neither human nor 
veterinary use through the centralized procedure.
I 5. Conclusion
Acetylfentanyl is a synthetic opioid. It is closely related to 
fentanyl, which is controlled under the United Nations Single 
Convention on Narcotic Drugs of 1961. Data suggests that 
acetylfentanyl is likely to be a potent opioid narcotic analgesic 
and may have an abuse liability and dependence potential in 
humans; these effects may be broadly comparable to fentanyl.
Acetylfentanyl has been available in the European Union since 
at least 2013 and has been detected in 8 Member States and 
Norway. In most cases it has been seized as a powder, but 
other forms such as liquids and tablets have also been 
detected. The detected quantities are relatively small; 
however, there is still a cause for concern given the high 
potency of the substance. It appears that acetylfentanyl 
usually originates from chemical companies based China. 
There is no indication of illicit production sites within the 
European Union. Acetylfentanyl is sold as a ‘research 
chemical’ online and is available in wholesale and consumer 
amounts up to 1kg. Acetylfentanyl was controlled in China in 
October 2015 and there may have been a decrease in the 
number of internet vendors offering the substance for sale 
since that time.
40 serious adverse events associated with acetylfentanyl 
have been reported by 4 Member States. These comprise 8 
acute intoxications requiring hospitalisation and 32 deaths; in 
19 of these deaths acetylfentanyl was the cause of death or 
contributed to the death. More than 90% of the deaths 
occurred in 2015.
Information on the use of acetylfentanyl in Europe is limited. It 
appears that acetylfentanyl is used as a drug in its own right, 
but, given the experiences in the United States, concerns exist 
that the drug could be supplied surreptitiously to users, 
including those who inject opioids.
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Acetylfentanyl is under assessment by the United Nations 
system — specifically, a critical review has been published 
and the drug was assessed at the 37th meeting of the WHO 
Expert Committee on Drug Dependence (ECDD) that was 
held on 16–20 November 2015. A recommendation from the 
assessment has not been published at the time of writing this 
Joint Report.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of acetylfentanyl, and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through a risk 
assessment procedure in accordance with Article 6 of Council 
Decision 2005/387/JHA. However, should the recommendation 
of the ECDD be published before or during the deliberations on 
this Joint Report, the Commission and the Council may wish to 
consider the implications of the recommendation when 
deciding on the need to request a risk assessment.
The EMCDDA and Europol will continue to intensively monitor 
acetylfentanyl in order to ensure that new information is 
provided to the Member States, the EMA, and the Commission 
via the information exchange of the European Union Early 
Warning System.
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